IRVINE, Calif., July 28 Cardiogenesis Corporation (Pink Sheets: CGCP), announced that the company will release results for its second quarter ended June 30, 2009 after market close on Thursday, August 13, 2009. The company also said that Executive Chairman Paul J. McCormick and Senior Vice President and Chief Financial Officer William R. Abbott will host an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to review the company's financial results and business outlook.
The call is open to all interested investors through a live audio web broadcast via the Internet at www.cardiogenesis.com and will also be available by dialing (800) 573-4754. The participant passcode is 39582034. The call will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.
For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.
SOURCE Cardiogenesis Corporation